简体中文 | 繁體中文 | English

Pharmaron

Pharmaron to Supply Nucleoside Phosphoramidites to Isis Pharmaceuticals

2011-03-17 14:21
  • zh_cn
  • zh_hant
  • en

 

BEIJING--(BUSINESS WIRE)--Pharmaron has signed an agreement to provide Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) with nucleoside phosphoramidites at quantities up to 100 kg. Nucleoside phosphoramidites are fundamental building blocks in the production of antisense therapeutics. Isis is the world’s leader in antisense therapeutics with a pipeline of 24 drugs in development.

Under the terms of this contract, Pharmaron will continue to provide Isis with certain nucleoside phosphoramidites during the next two years. Pharmaron has worked closely with Isis’ R&D team over the past three years and also provided high-quality materials for early discovery work.

“We have had a very successful working relationship with Pharmaron and are pleased to continue this partnership for two more years. Pharmaron has been an outstanding supplier of high-quality nucleoside phosphoramidites to Isis. The dependability and quality of the materials Pharmaron supplies to us allow us to focus our efforts on advancing our chemistries and technologies,” said Eric Swayze, Ph.D., Vice President, Medicinal Chemistry at Isis.

“Pharmaron is honored to continue to work with Isis Pharmaceuticals, a true pioneer and leader in the field of antisense therapeutics,” said Pharmaron Chairman and CEO Dr. Boliang Lou. “Our customers have come to depend on our high-quality R&D services, which we provide to pharmaceutical and biotech companies around the world.”

ABOUT PHARMARON

Pharmaron is a premier R&D service provider for the pharmaceutical and biotech industries. Founded in 2003, Pharmaron invests in its people and facilities enabling the Company to provide high quality R&D service across a number of disciplines, including chemistry, biology, DMPK, pharmacology and chemical development. Pharmaron is steadily growing to meet the needs of its customers. With more than 1,200 employees and operations in China and the U.S., Pharmaron delivers superior scientific services while maintaining close communication with customers. The Company’s current clients include small and large pharmaceutical companies in North America, Europe and Japan. Pharmaron's mission is to provide the highest quality R&D services while helping customers advance their projects in a timely and cost effective manner. More information is available at www.pharmaron.com.

Contacts

Chempetitive Group
Erik Clausen or Kena Hudson
510-908-0966
pharmaron@chempetitive.com
or
Pharmaron
Katherine Lee, 562-686-9786
klee@pharmaron.com